MPWT
BCRX icon

MassMutual Private Wealth & Trust’s BioCryst Pharmaceuticals BCRX Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-58
Closed -$520 – 2373
2025
Q2 		$520 Buy
+58
New +$540 ﹤0.01% 2217
2024
Q2 		– Sell
-70
Closed -$356 – 2139
2024
Q1 		$356 Sell
70
-204
-74% -$1.15K ﹤0.01% 1917
2023
Q4 		$1.64K Buy
274
+227
+483% +$1.31K ﹤0.01% 1566
2023
Q3 		$333 Buy
+47
New +$338 ﹤0.01% 1879

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MassMutual Private Wealth & Trust's BCRX Position: Q3 2025 in Review

MassMutual Private Wealth & Trust sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 58 shares — an estimated $520 sold.

MassMutual Private Wealth & Trust first reported a position in BCRX in Q3 2023 and held it in 4 quarters. The position peaked at $1.64K in Q4 2023. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • MassMutual Private Wealth & Trust reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 58 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $520.
  • MassMutual Private Wealth & Trust first reported a position in BioCryst Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • MassMutual Private Wealth & Trust's BioCryst Pharmaceuticals position peaked at $1.64K in Q4 2023.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on MassMutual Private Wealth & Trust's 13F filing for Q3 2025, filed 22 Oct 2025.